Literature DB >> 25642805

Eyes on MEGDEL: distinctive basal ganglia involvement in dystonia deafness syndrome.

Saskia B Wortmann1, Peter M van Hasselt2, Ivo Barić3, Alberto Burlina4, Niklas Darin5, Friederike Hörster6, Mahmut Coker7, Sema Kalkan Ucar7, Zita Krumina8, Karin Naess9, Lock H Ngu10, Ewa Pronicka11, Gilian Riordan12, Rene Santer13, Evangeline Wassmer14, Johannes Zschocke15, Manuel Schiff16, Linda de Meirleir17, Mohammed A Alowain18, Jan A M Smeitink1, Eva Morava19, Tamas Kozicz20, Ron A Wevers21, Nicole I Wolf22, Michel A Willemsen23.   

Abstract

Pediatric movement disorders are still a diagnostic challenge, as many patients remain without a (genetic) diagnosis. Magnetic resonance imaging (MRI) pattern recognition can lead to the diagnosis. MEGDEL syndrome (3-MethylGlutaconic aciduria, Deafness, Encephalopathy, Leigh-like syndrome MIM #614739) is a clinically and biochemically highly distinctive dystonia deafness syndrome accompanied by 3-methylglutaconic aciduria, severe developmental delay, and progressive spasticity. Mutations are found in SERAC1, encoding a phosphatidylglycerol remodeling enzyme essential for both mitochondrial function and intracellular cholesterol trafficking. Based on the homogenous phenotype, we hypothesized an accordingly characteristic MRI pattern. A total of 43 complete MRI studies of 30 patients were systematically reevaluated. All patients presented a distinctive brain MRI pattern with five characteristic disease stages affecting the basal ganglia, especially the putamen. In stage 1, T2 signal changes of the pallidum are present. In stage 2, swelling of the putamen and caudate nucleus is seen. The dorsal putamen contains an "eye" that shows no signal alteration and (thus) seems to be spared during this stage of the disease. It later increases, reflecting progressive putaminal involvement. This "eye" was found in all patients with MEGDEL syndrome during a specific age range, and has not been reported in other disorders, making it pathognomonic for MEDGEL and allowing diagnosis based on MRI findings. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25642805     DOI: 10.1055/s-0034-1399755

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  13 in total

1.  Teaching NeuroImage: Bilateral Nucleus Tractus Solitarius Lesions in Neurogenic Respiratory Failure.

Authors:  Bindu Parayil Sankaran; Saskia B Wortman; Michel A Willemsen; Shanti Balasubramaniam
Journal:  Neurology       Date:  2021-08-10       Impact factor: 9.910

Review 2.  Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders.

Authors:  Diana A Olszewska; Sapna Rawal; Conor Fearon; Paula Alcaide-Leon; Rick Stell; Vijayashankar Paramanandan; Tim Lynch; Tania Jawad; Padmaja Vittal; Brandon Barton; Hiroaki Miyajima; Satoshi Kono; Rukmini Mridula Kandadai; Rupam Borgohain; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2022-02-03

3.  First missense mutation outside of SERAC1 lipase domain affecting intracellular cholesterol trafficking.

Authors:  María Elena Rodríguez-García; Elena Martín-Hernández; Ana Martínez de Aragón; María Teresa García-Silva; Pilar Quijada-Fraile; Joaquín Arenas; Miguel A Martín; Francisco Martínez-Azorín
Journal:  Neurogenetics       Date:  2015-10-07       Impact factor: 2.660

4.  Adult-onset Generalized Dystonia as the Main Manifestation of MEGDEL Syndrome.

Authors:  Camille Giron; Emmanuel Roze; Bertrand Degos; Aurélie Méneret; Claude Jardel; Annie Lannuzel; Fanny Mochel
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-04-18

5.  The role of the clinician in the multi-omics era: are you ready?

Authors:  Clara D M van Karnebeek; Saskia B Wortmann; Maja Tarailo-Graovac; Mirjam Langeveld; Carlos R Ferreira; Jiddeke M van de Kamp; Carla E Hollak; Wyeth W Wasserman; Hans R Waterham; Ron A Wevers; Tobias B Haack; Ronald J A Wanders; Kym M Boycott
Journal:  J Inherit Metab Dis       Date:  2018-01-23       Impact factor: 4.982

6.  Dystonia is a Common Phenotypic Feature of MEGDEL Syndrome.

Authors:  Josef Finsterer; Fulvio A Scorza; Ana C Fiorini; Carla A Scorza; Antonio Carlos Almeida
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-05-29

Review 7.  Neurometabolic disorders: Five new things.

Authors:  Michèl A Willemsen; Inga Harting; Ron A Wevers
Journal:  Neurol Clin Pract       Date:  2016-08

8.  Incidental Finding of MEGDEL Syndrome Based on Neuroimaging: Case Report.

Authors:  Salma A Alshammari; Fouad A Alghamdi; Rami Alhazmi; Shaikhah Aldossary
Journal:  Case Rep Neurol       Date:  2021-06-28

9.  Transient neonatal renal failure and massive polyuria in MEGDEL syndrome.

Authors:  Carole Harbulot; Stéphanie Paquay; Imen Dorboz; Samia Pichard; Agnès Bourillon; Jean-François Benoist; Claude Jardel; Hélène Ogier de Baulny; Odile Boespflug-Tanguy; Manuel Schiff
Journal:  Mol Genet Metab Rep       Date:  2016-03-10

10.  Progressive deafness-dystonia due to SERAC1 mutations: A study of 67 cases.

Authors:  Roeltje R Maas; Katarzyna Iwanicka-Pronicka; Sema Kalkan Ucar; Bader Alhaddad; Moeenaldeen AlSayed; Mohammed A Al-Owain; Hamad I Al-Zaidan; Shanti Balasubramaniam; Ivo Barić; Dalal K Bubshait; Alberto Burlina; John Christodoulou; Wendy K Chung; Roberto Colombo; Niklas Darin; Peter Freisinger; Maria Teresa Garcia Silva; Stephanie Grunewald; Tobias B Haack; Peter M van Hasselt; Omar Hikmat; Friederike Hörster; Pirjo Isohanni; Khushnooda Ramzan; Reka Kovacs-Nagy; Zita Krumina; Elena Martin-Hernandez; Johannes A Mayr; Patricia McClean; Linda De Meirleir; Karin Naess; Lock H Ngu; Magdalena Pajdowska; Shamima Rahman; Gillian Riordan; Lisa Riley; Benjamin Roeben; Frank Rutsch; Rene Santer; Manuel Schiff; Martine Seders; Silvia Sequeira; Wolfgang Sperl; Christian Staufner; Matthis Synofzik; Robert W Taylor; Joanna Trubicka; Konstantinos Tsiakas; Ozlem Unal; Evangeline Wassmer; Yehani Wedatilake; Toni Wolff; Holger Prokisch; Eva Morava; Ewa Pronicka; Ron A Wevers; Arjan P de Brouwer; Saskia B Wortmann
Journal:  Ann Neurol       Date:  2017-12       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.